{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T20:19:57Z","timestamp":1649017197836},"reference-count":19,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1157\/13128730","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T17:56:19Z","timestamp":1227376579000},"page":"658-659","source":"Crossref","is-referenced-by-count":0,"title":["Leucemia mieloide cr\u00f3nica"],"prefix":"10.1016","volume":"131","author":[{"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13128730_bb0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous eukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1157\/13128730_bb0010","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1157\/13128730_bb0015","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1157\/13128730_bb0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13128730_bb0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13128730_bb0030","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13128730_bb0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from a panel expert on behalf of the European Leukemianet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0040","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0045","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinestics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0050","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0055","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia-chromosome postive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13128730_bb0060","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable, durable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0065","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure or first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0070","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia-chromosome positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1157\/13128730_bb0075","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0080","doi-asserted-by":"crossref","first-page":"155a","DOI":"10.1182\/blood.V110.11.473.473","article-title":"Bosutinib (SKI-606) demonstrates clinical activity among patients with AP and BP CML and Ph+ ALL","volume":"110","author":"Gambacorti-Paserini","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0085","doi-asserted-by":"crossref","first-page":"144a","DOI":"10.1182\/blood-2007-03-080689","article-title":"A phase I study of INNO-406 in patients with advanced Philadelphia (Ph) chromosome-positive leukemias who are resistant or intolerant to imatinib and second-generation tyrosine kinase inhibitors","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0090","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1157\/13128730_bb0095","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308754617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775308754617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T19:01:18Z","timestamp":1589137278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775308754617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":19,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0025775308754617"],"URL":"https:\/\/doi.org\/10.1157\/13128730","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}